Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship
- J Med Chem. 2008 Aug 14;51(15):4601-8. doi: 10.1021/jm800257s.
- 1. Department of Medicinal Chemistry, Prassis Istituto di Ricerche Sigma-Tau SpA, Via Forlanini 3, Settimo Milanese, MI, Italy. [email protected]
We report the synthesis and biological properties of novel inhibitors of the Na(+),K(+)-ATPase as positive inotropic compounds. Following our previously described model from which Istaroxime was generated, the 5alpha,14alpha-androstane skeleton was used as a scaffold to study the space around the basic chain of our lead compound. Some compounds demonstrated higher potencies than Istaroxime on the receptor and the (E)-3-[(R)-3-pyrrolidinyl]oxime derivative, 15, was the most potent; as further confirmation of our model, the E isomers of the oxime are more potent than the Z form. The compounds tested in the guinea pig model induced positive inotropic effects, which are correlated to the in vitro inhibitory potency on the Na(+),K(+)-ATPase. The finding that all tested compounds resulted less proarrhythmogenic than digoxin, a currently clinically used positive inotropic agent, suggests that this could be a feature of the 3-aminoalkyloxime derivative class of 5alpha,14alpha-androstane.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cardiovascular Disease
-
target: Na+/K+ ATPaseResearch Areas: Cardiovascular Disease